Ipilimumab, a monoclonal antibody targeting CTLA-4, has been approved by the FDA for the treatment of melanoma and specific lung cancers.347 It is actively under investigation in numerous clinical trials for its potential in treating CRC in combination with other therapeutic agents. Here, CTLA4 is linked to colorectal carcinoma.